Holen Sie sich die Stockscreener-App
20.94
3.41%
0.70
Schlusskurs vom Vortag:
$20.24
Offen:
$20.15
24-Stunden-Volumen:
378.26K
Relative Volume:
0.45
Marktkapitalisierung:
$860.63M
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
14.44
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
+1.36%
1M Leistung:
-19.56%
6M Leistung:
-6.69%
1J Leistung:
-6.77%
1-Tages-Spanne:
$20.15
$21.12
1-Wochen-Bereich:
$18.80
$21.12
52-Wochen-Spanne:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
20.94 | 831.86M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
124.05 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.65 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.62 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira partners with LG Chem to make EXPAREL® available in select APAC markets - BioSpectrum Asia
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st
Benign Growth For Pacira BioSciences, Inc. (NASDAQ:PCRX) Underpins Stock's 28% Plummet - 富途资讯
Pacira BioSciences Inc (PCRX) Stock Price Down 5.4% on Jan 16 - GuruFocus
Market Outlook: Is Great Elm Group Inc subject to activist investor interestPortfolio Performance Summary & Smart Swing Trading Alerts - baoquankhu1.vn
Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week LowTime to Sell? - MarketBeat
Do Options Traders Know Something About Pacira BioSciences Stock We Don't? - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Connect - ACCESS Newswire
Pacira BioSciences (NASDAQ:PCRX) Shares Down 6.9%What's Next? - MarketBeat
Pacira drops after adjusting 2025 revenue below consensus - MSN
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific - Finviz
Pacira BioSciences Signs Deal With LG Chem To Commercialize EXPAREL In Select Asia-Pacific Markets - Nasdaq
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets By Investing.com - Investing.com India
LG Chem to distribute Pacira’s EXPAREL in Asian-Pacific markets - Investing.com
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets - The Manila Times
Opioid-sparing EXPAREL to reach patients in South Korea and Thailand - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring a 29.59% Potential Upside in Non-Opioid Pain Management Solutions - DirectorsTalk Interviews
Behavioral Patterns of PCRX and Institutional Flows - Stock Traders Daily
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - sharewise.com
Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt? - 富途牛牛
Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist PressureHas The Bull Case Changed? - Sahm
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2026-01-11 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Assessing Pacira BioSciences (PCRX) Valuation After Record EXPAREL Quarter Buybacks And Activist Pressure - Sahm
Pacira Stock (-9.6%): EXPAREL Decel Spooks the Street - Trefis
How Investors May Respond To Pacira BioSciences (PCRX) Activist Pressure Amid Buybacks And Rising EXPAREL Revenue - Yahoo Finance
Pacira BioSciences (NASDAQ:PCRX) Shares Gap DownHere's What Happened - MarketBeat
Is Pacira BioSciences Inc. (82P) stock supported by strong fundamentalsNew Releases Roundup & walk-ready comfort choices - ulpravda.ru
HC Wainwright Reaffirms Buy Rating for Pacira BioSciences (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences' (PCRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Pacira BioSciences (PCRX) Rating Reiterated as 'Buy' by HC Wainw - GuruFocus
What Analysts Are Saying About Pacira BioSciences Stock - Benzinga
Pacira BioSciences (PCRX) Receives 'Buy' Rating from Needham | P - GuruFocus
Pacira BioSciences Stock Pre-Market (-9.7%): Weak Preliminary 2025 Revenue - Trefis
Will Pacira BioSciences Inc. stock benefit from AI adoptionJuly 2025 Big Picture & Growth Focused Investment Plans - Улправда
Why Pacira BioSciences Inc. stock remains resilient2025 Big Picture & Detailed Earnings Play Strategies - Улправда
Signal Recap: Will Pacira BioSciences Inc. stock continue upward momentumJuly 2025 Catalysts & Short-Term High Return Ideas - Улправда
Pacira BioSciences (PCRX) Shares Dip After Revenue Outlook Cut - GuruFocus
Pacira (PCRX) Reports Strong 2025 Performance, Eyes Future Growt - GuruFocus
Pacira reports record EXPAREL sales with 7% volume growth in Q4 By Investing.com - Investing.com South Africa
Pacira reports record EXPAREL sales with 7% volume growth in Q4 - Investing.com
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues - The Manila Times
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 8, 2025. - MarketScreener
Is Pacira BioSciences Inc. stock dividend yield sustainableJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - Улправда
Is Pacira BioSciences Inc. (82P) stock attractive post correctionShort Setup & Long-Term Growth Plans - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences - markets.businessinsider.com
Lauren Riker Sells 1,416 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock - MarketBeat
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):